Related Experiment Video
Updated: Jan 2, 2026
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.4K
The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population
Dusty Lisi1, Ebony Andrews2, Chelsea Parry1
1Department of Pharmacy Practice, School of Pharmacy, Georgia Campus-Philadelphia College of Osteopathic Medicine, 625 Old Peachtree Rd NW, Suwanee, GA, 30024, USA.
Cardiovascular Drugs and Therapy
|December 6, 2019
Summary
Ranolazine, an anti-anginal drug, shows potential benefits for glycemic control in patients with diabetes. This review explores its antihyperglycemic effects and suitability for patients with both angina and diabetes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Ranolazine is approved for chronic angina and exhibits pleiotropic effects on various cardiac conditions.
- Emerging research suggests ranolazine may improve glycemic control.
- The cardiovascular risks associated with diabetes highlight the need for treatments addressing both conditions.
Purpose of the Study:
- To review clinical data on ranolazine's antihyperglycemic effects.
- To explore potential mechanisms behind ranolazine's glucose-lowering properties.
- To assess ranolazine's utility in patients with comorbid chronic angina and diabetes.
Main Methods:
- Systematic review of clinical studies on ranolazine.
- Analysis of data regarding ranolazine's impact on glycemic parameters.
- Evaluation of potential mechanisms including beta-cell function and insulin secretion.
Main Results:
- Ranolazine demonstrates promising results in improving glycemic control.
- Potential mechanisms involve beta-cell preservation and modulation of insulin secretion.
- The drug may offer a dual benefit for patients with angina and diabetes.
Conclusions:
- Ranolazine presents a potential therapeutic option for managing comorbid chronic angina and diabetes mellitus.
- Further research is needed to elucidate the precise mechanisms and define optimal patient populations for its antihyperglycemic effect.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.2K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
01:06Oral Hypoglycemic Agents: Glinides
537
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
537
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
543
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
543
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.6K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.6K
01:24Glucagon-like Receptor Agonists
786
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
786
01:15Diabetes: Management and Pharmacotherapy
809
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
809